Our partners have run the organizations that buy what our portfolio sells: a $3.3B capitated care-delivery organization, value-based contracts covering 200,000 lives, FDA-cleared diagnostic platforms, and frontline surgical care. We evaluate every company from the perspective of the health system, payer, or clinician who has to adopt it, pay for it, and live with it.

Our syndicate spans dozens of medical and surgical specialties, and its members are the end users of the products we evaluate. Before we invest, practicing clinicians and operators pressure-test whether a product actually removes work, changes decisions, and survives contact with real clinical practice, not just whether the demo looks elegant.

Every opportunity moves through our proprietary diligence tools, which separate evidence from inference from assumption while testing workflow ownership, clinical evidence, reimbursement, regulatory pathway, commercial adoption, and expansion potential. The same discipline is applied to every deal, in every thesis.

We do not chase categories. We underwrite a specific pattern: companies that solve one high-value problem, earn ownership of a critical workflow, accumulate differentiated data, and expand from that position. Our principle is simple: price the wedge, not the platform. It keeps us disciplined when the market is not.

Our value does not end at the wire. Syndicate members open doors to health systems, payers, and specialty practices; validate clinical utility in new markets; and help founders navigate the long sales cycles and entrenched incumbents that define healthcare. When we back a company, the network goes to work.